Investigational device for patients with non-valvular afib
Matthew J Price, M.D.
This trial is evaluating the safety and effectiveness of the Amulet device compare to NOAC (non-vitamin K antagonist oral anticoagulants) therapy in patients with non-valvular atrial fibrillation (Afib) at increased risk for ischemic stroke and who are recommended for long tern NOAC therapy.
Be at high risk of stroke or systemic embolism, defined as a CHA2DS2-VASc score of = 3
Be eligible for long-term NOAC therapy
Be 18 years of age or older
Meet all other eligibility criteria
Patients must not:
Require long-term OAC therapy for a condition other than afib
Have a history of rheumatic or congenital mitral valve heart disease
All treatments and physician visits during this study will take place at Scripps Clinic Anderson Medical Pavilion.
For more information, search for NCT# 04226547 at www.clinicaltrials.gov